The Potential of HSP Inhibitors as Radiation Sensitizers
Laurie Gaspar, MD, from the University of Colorado School of Medicine, discusses the potential of heat shock protein (HSP) inhibitors as radiation sensitizers.
Laurie Gaspar, MD, Professor and Chair Department of Radiation Oncology, Grohne Chair in Clinical Oncology, University of Colorado School of Medicine, discusses the potential of heat shock protein (HSP) inhibitors as radiation sensitizers.
Currently, most of the research in this setting has been preclinical. Gaspar believes that this would be a promising area for HSP inhibitors, as they could be combined with a smaller dose of radiation, and consequently limit the side effects.
Clinical Pearls
Gaspar says that the radiation-sensitizing potential of HSP inhibitors could exist in any cell, but may work best in radiation-resistant cells. This could be the right time to move this theory into the clinical setting for lung cancer.
- There has been some preclinical research into using heat shock protein (HSP) inhibitors as a radiation sensitizer in lung cancer
- HSP inhibitors as a radiation sensitizer could lessen the dose, and the side effects, of radiation therapy
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
